» Articles » PMID: 31532756

Long Non-coding RNA TUG1 Enhances Chemosensitivity in Non-small Cell Lung Cancer by Impairing MicroRNA-221-dependent PTEN Inhibition

Overview
Specialty Geriatrics
Date 2019 Sep 19
PMID 31532756
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Long non-coding RNA taurine up-regulated gene 1 (TUG1) emerges as new players in gene regulation in several cancers; however, its mechanism of action in non-small cell lung cancer (NSCLC) has not been well-studied. Herein, we determined expression pattern of TUG1 in NSCLC and further identified its effect on the chemosensitivity of NSCLC. Low expression of TUG1 was found in NSCLC tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival. TUG1 overexpression was shown to inhibit cell proliferation, migration, invasion, but facilitate apoptosis and autophagy in NSCLC cells resistant to cisplatin (DDP). Smaller size of tumor xenografts of DDP resistant NSCLC cells in the presence of TUG1 demonstrated enhancement of chemosensitivity by TUG1 . High expression of miR-221 and low expression of PTEN were determined in cancer tissues obtained from non-responders to platinum-based chemotherapy and reflected poor overall survival. TUG1 inhibited miR-221 that targeted PTEN, as evidenced by an elevated expression of PTEN in the presence of miR-221 or the absence of TUG1. Our present study reveals a model of enhancement of chemosensitivity that consists of TUG1, miR-221 and PTEN. Modulation of their levels may offer a new approach for improving anti-tumor efficacy for chemotherapeutic agents in NSCLC.

Citing Articles

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.


Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.

Sonobe R, Yang P, Suzuki M, Shinjo K, Iijima K, Nishiyama N Cancer Sci. 2024; 115(6):1910-1923.

PMID: 38558246 PMC: 11145130. DOI: 10.1111/cas.16150.


Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village.

Ao Y, Gao J, Jiang J, Wang H, Wang S, Ding J Mol Ther. 2023; 31(12):3389-3413.

PMID: 37740493 PMC: 10727995. DOI: 10.1016/j.ymthe.2023.09.015.


LINC01305 recruits basonuclin 1 to act on G-protein pathway suppressor 1 to promote esophageal squamous cell carcinoma.

Xiong L, Tan J, Zhang R, Long Q, Xiong R, Liu Y Cancer Sci. 2023; 114(11):4314-4328.

PMID: 37705202 PMC: 10637064. DOI: 10.1111/cas.15963.


Autophagy-related lncRNAs in tumor progression and drug resistance: A double-edged sword.

Zhang Y, Tang J, Wang C, Zhang Q, Zeng A, Song L Genes Dis. 2023; 11(1):367-381.

PMID: 37588204 PMC: 10425854. DOI: 10.1016/j.gendis.2023.04.015.


References
1.
Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

2.
Chalhoub N, Baker S . PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2008; 4:127-50. PMC: 2710138. DOI: 10.1146/annurev.pathol.4.110807.092311. View

3.
Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L . Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018; 9(7):761-768. PMC: 6026617. DOI: 10.1111/1759-7714.12652. View

4.
Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

5.
Perez-Ramirez C, Canadas-Garre M, Molina M, Faus-Dader M, Angel Calleja-Hernandez M . PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015; 16(16):1843-62. DOI: 10.2217/pgs.15.122. View